Cereno Scientific is developing a unique concept for the prevention of blood clots - the biggest cause of death in the world. The company aims to bring to market a new preventive medicine to treat thrombosis-related disease, offering an opportunity for effective treatment while lowering the risk of serious bleeding complications associated with current treatment with blood-thinning drugs - leading to more effective treatment.
Following the recent news of positive milestone progress for the formulation development of Cereno Scientific’s candidate drug CS1, the appointment of Professor Wolzt as Senior Advisor R&D and positive data in the in vivo study – with results published Q4 2016 in the Journal of Thrombosis and Haemostasis (JTH) – showing preventive effect of thrombosis and no increased bleeding in mice of its active substance, the company is gearing up for a first clinical study with CS1 in Q3, 2017.
Cereno Scientific's CEO, Sten R Sörensen, comments:
“We are very pleased to work with CTC as our CRO partner as we enter the clinical phase of development with CS1. CTC has the necessary expertise and capabilities in-house - from protocol design to reporting - combined with their own clinical research unit.”
CTC’s CEO, Anders Millerhovf, adds:
“We are very happy for this collaboration with Cereno Scientific, We look forward to work with their interesting drug candidate CS1 and are currently working full-speed with the study preparations.”
For more information, please contact:
Sten R. Sörensen – Chief Executive Officer
Telephone: +46 73 374 03 74.
About Cereno Scientific AB
Cereno Scientific develops preventive medicines to treat thrombosis-related disease, such as myocardial infarction and stroke. These novel therapeutics stimulate the body's own intelligent clot-busting system, and are being developed to treat thrombosis-related cardiovascular diseases on the global market. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn leads to a high risk of new blood clots. The benefit with Cereno Scientific's drug candidate, CS1, is an improved balance between preventing blood clots and treatment-related side effects - leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. It is based on many years of research and its effectiveness on risk factors is documented in experimental studies and early clinical studies. Preventive effectiveness against blood clots has been demonstrated in animal in vivo studies. Indication of clinical preventive effectiveness against heart attacks has been demonstrated in two large epidemiological studies. CS1 has a unique mechanism of action, a potentially wide range of indication opportunities connected to large blood clot-related diseases and, consequently, a large market potential. The Göteborg-based company is listed on the AktieTorget stock market, conducts research activities at AstraZeneca's BioVentureHub in Göteborg and is supported by GU Ventures. For more information, see www.cerenoscientific.se.
About CTC Clinical Trial Consultants AB
CTC is a Swedish full-service CRO with clinical conduct in focus. Our mission is to facilitate clinical and translational research by providing our customers cost-effective advice and implementation of early clinical trials
(Phase 0 / I / IIa). CTC has two dedicated research clinics in Uppsala (12 hospital beds, 12 non-hospital beds) in combination with two patient clinics located both in Uppsala and Linköping. Read more at ctc-ab.se